Search
for
Sort by
Research
540-570 / 1000+ results
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Janus kinase (JAK)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin
High levels of ODC and a mutant Ha-ras gene cause tumors in mice.
research Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research Treatment of alopecia areata with JAK inhibitors: a review of the literature
JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
research Cutaneous adverse effects of targeted therapies
Targeted cancer therapies often cause skin side effects, needing dermatologist care.
research The manipulation of the cedrol metabolism pathway by baricitinib and its immune interaction mechanism against chemotherapy-induced alopecia
research COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
Baricitinib works better than methotrexate for severe alopecia areata.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Janus kinase inhibitors for alopecia areata: A narrative review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Hair Loss in a Hemodialysis Patient after Repetitive Use of the Antipruritic Drug Nalfurafine: Implications of Impaired Angiogenesis for Hair Loss
Stopping nalfurafine reversed hair loss in a hemodialysis patient.
research The Double-Edged Sword of Epidermal Growth Factor Receptor Inhibitor: Rash as Toxicity and Prognostic Marker
Rash from EGFRI treatment can indicate both side effects and treatment effectiveness.
research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.
research Hair for the Long Haul: Alopecia Areata Cases and Considerations
JAK inhibitors are effective for long-term management of alopecia areata.
research Use of Single‐Cell Data and scPagwas Analysis to Identify T Cell Subsets and Construct a Prognostic Model for Clear Cell Renal Cell Carcinoma
T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.
research 710 BIOMARKERS OF SUNITNIB CLINICAL RESPONSE IN METASTATIC RENAL CLEAR CELL CARCINOMA PATIENTS
research Protein Kinase C as a Therapeutic Target
Protein Kinase C shows promise for cancer treatment, but more research is needed to develop effective inhibitors.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Glycyrrhizic Acid Alleviates Osimertinib‐Induced Cutaneous Toxicity by Inhibiting Keratinocyte Apoptosis and Inflammation
Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research hsa_circ_0002980 prevents proliferation, migration, invasion, and epithelial-mesenchymal transition of liver cancer cells through microRNA-1303/cell adhesion molecule 2 axis
hsa_circ_0002980 can help stop liver cancer cells from growing and spreading.
research Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
Baricitinib reduces inflammation and mitochondrial damage in skin cells.